Daniel Smith

Daniel Smith serves as Vice President of Translational Medicine at Alkermes since May 2018, where responsibilities include creating and executing strategies for novel treatments in neurological, psychiatric, and rare diseases. Prior to this role, Daniel held several key positions at BlackThorn Therapeutics and Autism Speaks, focusing on building R&D capabilities and advancing neuroscience therapies. Experience at Pfizer and Lundbeck involved leading projects in neuroscience research and development. Daniel earned a Ph.D. in Neuroscience from Purdue University and completed a postdoctoral fellowship at Eli Lilly and Company.